WiTNNess

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-09-23

Study Completion Date

2027-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

WiTNNess is designed to accurately document the natural course and variation of muscle disease caused by pathogenic changes of the TNNT1 gene. The primary aim of the study is to specify meaningful outcome measures for future clinical trials. WiTNNess is open to children and adults worldwide. Participants can choose to include their information once (cross-sectional cohort) or every few months (prospective cohort).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Improvement of DIAgnostic and Phenotype-genotype Correlation Studies in Patients With MYOpathy Suspected of TITinopathy

NCT03998540

Myopathy Phenotypic Abnormality Genetic Disease

RECRUITING

Multicenter Observational Study of Myotonic Dystrophy Type 1

NCT02308657

Myotonic Dystrophy Type 1

COMPLETED

Natural History Study of Mitochondrial Myopathy

NCT05250375

Primary Mitochondrial Disease

RECRUITING

Study of Muscle Wasting and Altered Metabolism in Patients With Myotonic Dystrophy

NCT00004769

Myotonic Muscular Dystrophy

COMPLETED

Nemaline Myopathy Clinical Research Network (NM-CTRN)

NCT06774703

Nemaline Myopathy

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

WiTNNess is an observational study that includes prospective and cross-sectional arms, both of which include people diagnosed with autosomal recessive TNNT1-associated muscle disease, commonly described as a form of infantile-onset (NEM5A) or childhood-onset (NEM5B) nemaline rod myopathy. The study's primary objective is to establish the nature and time course of disease outcomes under current treatment, so that these can later be compared to outcomes achieved with novel disease-modifying therapies (i.e., interventional trials).

Participants from all over the world are welcome to enroll in either arm of the WiTNNess study. Following appropriate consent, those in the prospective arm are followed long-term. Recurring assessments are performed at the participant's home, the Clinic for Special Children, or a partnering clinical site, depending on the individual's particular circumstances. Basic assessments include vital signs, a physical exam, documentation of motor milestones, growth measurements, and blood chemistry values. Participant's may also undergo non-invasive ultrasound of the heart (echocardiogram) and one or more chest radiographs.

Participants in the cross-sectional arm are contacted once after consent. Members of the WiTNNess study team partner with healthcare providers and family members to capture pertinent medical history, physical exam findings, growth metrics, and motor milestones at the time of contact.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

TNNT1-associated Myopathy Infantile-onset Nemaline Rod Myopathy Myopathies, Nemaline Myopathy Myopathy, Rod Myopathy; Hereditary Amish Nemaline Myopathy Nemaline Myopathy 5 NEM5 Genetic Muscle Disease Recessive Hereditary Disorder (Autosomal) ANM

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Prospective

Participants in the prospective cohort are enrolled during early infancy, shortly after diagnosis, and followed longitudinally with repeated assessments until reaching the primary study outcome.

No interventions assigned to this group

Cross-Sectional

Participants in the cross-sectional cohort enroll at any time after diagnosis and all study data are collected at a single time point.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with biallelic pathogenic variants of TNNT1
* Infantile-onset or childhood-onset proximal weakness without confounding medical conditions that could effect muscle health.

Exclusion Criteria

* Another known or suspected medical condition (genetic or acquired) that could potentially alter the natural disease course or otherwise interfere with completion of study procedures.

Eligible Sex

ALL

Accepts Healthy Volunteers

No